Phosphorylation-dependent regulation of SPOP by LIMK2 promotes castration-resistant prostate cancer.

While genomically altered SPOP-bearing tumours require gene therapy, uncovering LIMK2-SPOP relationship provides a powerful opportunity to retain WT-SPOP by inhibiting LIMK2, thereby halting disease progression.